Eleven Biotherapeutics

Eleven Biotherapeutics

Eleven Biotherapeutics was founded to develop protein-based cancer therapies through its proprietary protein engineering platform. The company's work centered on creating novel biologics, including a pipeline of candidates targeting solid tumors. Its research efforts were primarily funded through venture capital investments and strategic partnerships, though specific founding year and founding team names are not widely publicized. The firm's strategy involved preclinical and clinical-stage development of therapeutic proteins, with a focus on oncology. Asset-class coverage spanned early-stage research programs, and the company engaged in collaboration agreements with larger pharmaceutical entities to advance its technology. Named portfolio companies or specific co-investors are not publicly documented, and geographic footprint is limited to the Cambridge, Massachusetts area. Scale and team size details for Eleven Biotherapeutics are not publicly available. The firm does not list additional offices or disclose professional headcount. No adjacent vehicles or philanthropic structures have been identified, and no verifiable operational events from the last 24 months have been reported. Eleven Biotherapeutics' structural differentiator lies in its focus on protein engineering for oncology, a niche within biotechnology that emphasizes computational design and optimization of therapeutic proteins. The company's platform aimed to improve drug specificity and stability, though its path to commercialization remains unconfirmed in public sources.